NEW YORK, March 30 (Reuters) - Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy. Doctors who raised doubts about it received death threats. Health regulators ...

November 18, 2010 — The prostate cancer vaccine sipuleucel-T (Provenge, Dendreon) received a middling vote of confidence for its on-label use and what amounted to a thumbs-down vote for its off-label ...

WASHINGTON - Medicare officials confirmed Thursday that the program will cover the $93,000 price tag for prostate-cancer drug Provenge, an innovative therapy that typically gives men suffering from an ...

LOS ANGELES (Reuters) - Men in the U.S. Medicare health insurance program will get full coverage of Dendreon Corp's prostate cancer therapy under a proposed payment decision by U.S. regulators ...

NEW YORK, Oct 11 (Reuters) - In Dendreon Corp's most important clinical trial for the controversial cancer therapy Provenge, researchers analyzed some of the data differently from how the company told ...

announced today that four abstracts featuring PROVENGE^® (sipuleucel-T) data from ongoing Phase II sequencing studies and the PROCEED registry, and two abstracts highlighting preliminary Phase II data ...

WASHINGTON - A first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval Thursday, offering an important alternative to more taxing ...

Dendreon filed for bankruptcy protection on Monday after sales of Provenge fell way short of expectations and the company could not pay off a huge debt coming due. By Andrew Pollack Costly treatments ...

The facility will be used as office space, a warehouse, a laboratory and a manufacturing center.Dendreon has signed an agreement to lease 158,242 sq. ft. of manufacturing space in Hanover to make a ...

Medicare officials said Wednesday that the program will pay the $93,000 cost of prostate cancer drug Provenge, an innovative therapy that typically gives men suffering from an incurable stage of the ...